Genmab stock holds firm as royalties and pipeline draw eyes
Published on 08/22/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab A/S (DK0010272202) stock traded at DKK 1,999.00 in a recent Nasdaq Copenhagen quote, while MarketScreener showed a market capitalization of 73.03 billion and listed a 2026 P/E ratio of 21.5x.
Royalty flow still matters
That same quote set also flagged a single-session move of +6.50% in one market snapshot, giving the shares a clear dated reference point. The company also gets fresh attention from royalty income tied to DARZALEX, a business line that remains central to Genmab’s earnings profile.
StockAnalysis listed revenue of $3.65 billion on a trailing basis and pointed to third-quarter 2025 DARZALEX net sales of $3,672 million, which underscores how one partner product continues to anchor the model. For comparison, the 2026 valuation line of 21.5x P/E sits above the 2025 line of 17.5x, a concrete gap that shows how the market is pricing next-year earnings power.
Valuation and peer lens
The stock picture is also shaped by the gap between a DKK 1,999 quote and the DKK 2,055 close shown in the same quote history, a difference of DKK 56.00. That kind of move keeps the focus on whether earnings and royalty growth can justify the multiple.
In a broader Nordic healthcare context, Genmab sits among names where market cap and earnings expectations matter more than headline drama. The clean read for investors is that the valuation story now depends on whether product royalties and newer pipeline assets can keep feeding the top line.
Darzalex remains central
Genmab's flagship royalty stream comes from daratumumab-related oncology sales, which is why every change in partner volume matters for the Danish company. The latest cited figure of $3,672 million in third-quarter 2025 net sales shows the scale behind that royalty engine.
Shares and market level
Genmab stock was quoted at DKK 1,999.00, with market cap shown at 73.03 billion and a 2026 P/E ratio of 21.5x. That combination leaves the shares tied closely to the next round of operating updates and royalty flow rather than to a single headline event.
Fact box
Company: Genmab A/S
ISIN: DK0010272202
Ticker: GMAB
Exchange: Nasdaq Copenhagen
Price (as of December 22, 2025, 3:42 a.m. ET): DKK 1,999.00
Market cap: 73.03 billion
Sector / Industry: Healthcare / Biotechnology
Index membership: OMX Copenhagen 25
